Search

everythingexperts & clinicslearnfaqsresearchcommunity

for

Search:↓

Certain genetic differences may affect how likely someone is to get COVID-19 and how severe it might be.

This systematic review found that antiandrogens do not appear to protect against SARS-CoV-2 infection or reduce COVID-19 severity, suggesting their use is not advisable for COVID-19 treatment.

This study presents a new method using primary human lung tissue cells to rapidly identify viral entry factors and therapeutics for SARS-CoV-2, revealing compounds overlooked by conventional screening systems.

In this study, researchers developed a rapid platform using primary human lung tissues to identify SARS-CoV-2 targets and test antiviral compounds, achieving highly reproducible results across viral variants.

This article is a letter to the editor discussing late unexpected consequences of COVID-19 infection in individuals who survived acute hypoxic respiratory failure and includes no new research results.

This review discusses biological sex differences in COVID-19 outcomes and reports no new clinical results; it identifies a need for studies to clarify how sex influences disease progression.

Male pattern hair loss could hint at androgens affecting COVID-19 severity.

This review suggests that understanding the biological and molecular reasons for more severe COVID-19 in men, particularly those at risk for prostate cancer, could improve management of these patients, but reports no new results.

This review examines testosterone's role in male health and aging but reports no new clinical results; the authors highlight the need for further research on optimal testosterone levels to prevent age-related conditions.

Anti-androgens, like finasteride, dutasteride, and spironolactone, may lessen the severity of COVID-19 in men, leading to fewer ICU admissions.

This letter discusses the potential connection between androgenetic alopecia and COVID-19, suggesting a possible new therapy, but it reports no new results.

This study found that 5-alpha-reductase inhibitors were associated with a reduced frequency of COVID-19 symptoms in males with androgenetic alopecia.

This study noted that among hospitalized COVID-19 patients, androgenetic alopecia was prevalent, and severe cases were associated with adverse outcomes such as respiratory failure, highlighting a possible link with androgen sensitivity.

This study found that both extensive grey hair and alopecia were independently associated with increased COVID-19 severity among survey respondents in Brazil.

This publication is a letter discussing the association between an androgen receptor genetic variant and COVID-19 disease severity in hospitalized male patients, but it reports no new research results.

This review reports that women with polycystic ovary syndrome are at 28%–50% higher risk of SARS-CoV-2 infection, with increased rates of COVID-19-related hospitalization, morbidity, and mortality.

This review analyzes the potential mechanisms by which SARS-CoV-2 may exacerbate symptoms of benign prostatic hyperplasia and suggests a connection via ACE2 and androgen receptor pathways; it reports no new clinical results.

This review discusses hypopituitarism's bidirectional relationship with COVID-19 due to metabolic comorbidities and pituitary risks, but it reports no new clinical results.

This study found that telogen effluvium, a type of hair loss, was prevalent among 24% of COVID-19 patients, likely triggered by stress and medication related to the illness.

This review discusses the potential link between androgenic alopecia, androgens, and the severity of COVID-19, highlighting possible therapeutic targets but reports no new clinical results.

This study found that a 14-day treatment with proxalutamide significantly reduced the 28-day mortality rate in hospitalized COVID-19 patients compared to placebo, with greater benefits observed among those who adhered to the treatment.

This letter reports no new findings and discusses potential concerns regarding 5-alpha reductase inhibitors on lung function, suggesting a reason for discontinuation during the COVID-19 pandemic.

This study found no significant correlation between androgenetic alopecia or other hyper-androgenic skin manifestations and the severity of COVID-19 outcomes in hospitalized patients.

This review discusses the potential link between androgen deficiency and increased COVID-19 severity in aging men, but reports no new clinical results; it suggests that low testosterone levels may pose a risk factor.

This review discusses the relationship between hyperandrogenic conditions like PCOS and COVID-19, noting that while hyperandrogenic women have varied hospitalization rates, they do not show increased mortality, and suggests isotretinoin as a potential therapeutic option for cutaneous symptoms.

This study reported that testosterone replacement therapy was not linked to worse COVID-19 outcomes in men, though the data showed high hospitalization and fatality rates that suggest otherwise.

In a hamster model of COVID-19, this study observed that both low and high doses of testosterone worsened illness in males, while finasteride prevented severe outcomes.

This review examines existing research on androgen deprivation therapy and its effects on male sex hormones in relation to COVID-19, but reports no new clinical findings.

This paper reports no new results; it addresses the effects of Dutasteride on testosterone and DHT in men, and discusses the implications for androgen deprivation and COVID-19 outcomes.

PrEP doesn't increase STI risk in high-risk men, anti-androgen drugs may lower ICU admission for male COVID-19 patients, a 3-point injection is better for crow's feet, and the 'Geriatric-8' tool could help assess frailty in older skin cancer patients.